SHUTTLE PHARMACEUTICALS HOLD(NASDAQ:SHPH) stock Fundamental Analysis

Fundamental Rating

Overall SHPH gets a fundamental rating of 0 out of 10. We evaluated SHPH against 562 industry peers in the Biotechnology industry. Both the profitability and financial health of SHPH have multiple concerns. SHPH is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SHPH has reported negative net income.

SHPH had a negative operating cash flow in the past year.

In the past 5 years SHPH always reported negative net income.

In the past 5 years SHPH always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -364.87%, SHPH is doing worse than 96.09% of the companies in the same industry.

SHPH has a worse Return On Equity (-1289.63%) than 83.99% of its industry peers.

		Industry Rank	Sector Rank
ROA	-364.87%
ROE	-1289.63%
ROIC	N/A

ROA(3y)-170.32%

ROA(5y)-174.67%

ROE(3y)-496.91%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SHPH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, SHPH has more shares outstanding

SHPH has a worse debt/assets ratio than last year.

2.2 Solvency

SHPH has an Altman-Z score of -28.66. This is a bad value and indicates that SHPH is not financially healthy and even has some risk of bankruptcy.

SHPH has a worse Altman-Z score (-28.66) than 90.75% of its industry peers.

A Debt/Equity ratio of 1.23 is on the high side and indicates that SHPH has dependencies on debt financing.

With a Debt to Equity ratio value of 1.23, SHPH is not doing good in the industry: 79.18% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	1.23
Debt/FCF	N/A
Altman-Z	-28.66

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

SHPH has a Current Ratio of 1.44. This is a normal value and indicates that SHPH is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.44, SHPH is not doing good in the industry: 83.10% of the companies in the same industry are doing better.

A Quick Ratio of 1.44 indicates that SHPH should not have too much problems paying its short term obligations.

SHPH has a Quick ratio of 1.44. This is amonst the worse of the industry: SHPH underperforms 82.74% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.44
Quick Ratio	1.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SHPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.87%, which is quite good.

EPS 1Y (TTM)9.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-443.32%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SHPH. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SHPH!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SHUTTLE PHARMACEUTICALS HOLD

NASDAQ:SHPH (5/16/2025, 7:43:05 PM)

After market: 0.207 -0.01 (-4.17%)

0.216

-0.01 (-2.79%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2022-11-14/bmo

Earnings (Next)N/A N/A

Inst Owners9.43%

Inst Owner Change0%

Ins Owners19.48%

Ins Owner Change0%

Market Cap1.35M

AnalystsN/A

Price TargetN/A

Short Float %2.9%

Short Ratio0.03

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.91
P/tB	1.91
EV/EBITDA	N/A

EPS(TTM)-3.19

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-1.17

FCFYN/A

OCF(TTM)-1.17

OCFYN/A

SpS0

BVpS0.11

TBVpS0.11

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-364.87%
ROE	-1289.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-170.32%

ROA(5y)-174.67%

ROE(3y)-496.91%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	1.23
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.44
Quick Ratio	1.44
Altman-Z	-28.66

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)9.87%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-443.32%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-30.61%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-30.84%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-31.28%

OCF growth 3YN/A

OCF growth 5YN/A

SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens